Cargando…
SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration
BACKGROUND: The ability of a pharmacologic agent to reach target organ(s) in therapeutically-meaningful concentrations is one of the fundamental considerations when developing effective, anti-infective treatments. SCY-078 is a novel, oral and intravenous (IV), triterpenoid glucan synthase inhibitor...
Autores principales: | Barat, Stephen, Borroto-Esoda, Katyna, Angulo, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631121/ http://dx.doi.org/10.1093/ofid/ofx163.1204 |
Ejemplares similares
-
SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis
por: Borroto-Esoda, Katyna, et al.
Publicado: (2017) -
Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates
por: Barat, Stephen, et al.
Publicado: (2017) -
672. Activity of Ibrexafungerp (Formerly SCY-078) Against Candida auris: In vitro, In Vivo, and Clinical Case Studies of Candidemia
por: Barat, Stephen, et al.
Publicado: (2019) -
SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies
por: Scorneaux, Bernard, et al.
Publicado: (2017) -
Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis
por: Ghannoum, M., et al.
Publicado: (2018)